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Abstract
Pemphigus foliaceus (PF) is an organ-specific autoimmune skin disease characterized by subcorneal
epidermal cell detachment (acantholysis) and pathogenic autoantibodies against desmoglein 1. The
mechanism responsible for pemphigus autoantibody-induced epidermal injury is not fully
understood. In this study we used the IgG passive transfer mouse model of PF to investigate the
relevance of the apoptotic mechanisms in pemphigus pathogenesis. TUNEL-positive epidermal cells
and increased oligonucleosomes in the epidermal cytosolic fractions were detected in the diseased
mice. Time course study reveals that TUNEL-positive epidermal cells appear prior to intraepidermal
blisters. Moreover, the pro-apoptotic factor Bax was up-regulated at the earlier time points (2 and 4
h) while the anti-apoptotic factor Bcl-xl was down-regulated at the later time points (6, 8, and 20 h)
post PF IgG injection by Western blot analysis. The active forms of caspase-3 and -6 were detected
at the later time period (6, 8, and 20 h). Administration of Ac-DEVD-cmk, a peptide-based
caspase-3/7 inhibitor, protected mice from developing intraepidermal blisters and clinical disease
induced by PF IgG. The same protective effect was also observed using a broad-spectrum caspase
inhibitor, Bok-D-fmk. Collectively, these findings show that biochemical events of apoptosis are
provoked in the epidermis of mice injected with PF autoantibodies. Caspase activation may contribute
to acantholytic blister formation in PF.
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Pemphigus foliaceus (PF) and pemphigus vulgaris (PV) are the two classical forms of
pemphigus characterized by detachment of epidermal cells known as acantholysis and anti-
epidermal autoantibodies (1,2). Whereas PF displays intraepidermal blisters at the granular
layer and autoantibodies to the desmosomal glycoproteins desmoglein 1 (Dsg1), PV exhibits
intraepidermal blisters just above the basal cells and autoantibodies to Dsg3 (3,4). The IgG
fraction of the patients’ sera is pathogenic, as demonstrated by passive transfer experiments in
neonatal mice (5,6). Moreover, affinity-purified anti-Dsg1 and anti-Dsg3 IgG from patients’
sera are also pathogenic (7,8). There are other autoantibodies detected in the sera of pemphigus
patients, for example, autoantibodies against acetylcholine receptors (9) and E-cadherin (10).
The pathogenic role of these autoantibodies remains to be determined.
The molecular mechanism responsible for the acantholysis induced by pemphigus
autoantibodies has been a subject of intensive investigation in recent years. It has been generally
believed that binding of pemphigus autoantibodies to the ectodomain of Dsg3 or Dsg1 impairs
the adhesive function of these molecules thus causing acantholysis (11,12). However, recent
single-molecule atomic force microscopy studies show that in a cell-free system PF IgG does
not inhibit homophilic trans-interaction of Dsg1 molecules by steric hindrance (13), but PV
IgG directly inhibit Dsg3-mediated transinteraction (14). Cell culture studies has shown that
following the binding of PV autoantibodies to the cell surface, the antigen-antibody complex
is internalized into cytoplasmic vesicles and subsequently fused with lysosomes (15,16). The
autoantibody-mediated Dsg3 or Dag1 internalization and depletion from the cell surface is
accompanied by impaired desmosomal assembly/disassembly and decreased cell adhesiveness
(16–21).
Besides the two possible mechanisms-the steric hindrance and desmoglein depletion from the
cell surface, an increased body of evidence has demonstrated that pemphigus autoantibodies
are able to trigger intracellular events that may indirectly lead to acantholysis by yet unclear
mechanisms (22–30). Additionally, it has been hypothesized that keratinocyte apoptosis, in
response to binding of pemphigus autoantibodies, results in pemphigus acantholysis (31–35).
In vitro cell culture studies have shown that PV IgG or serum induces apoptosis (31,32,34–
36). The pro-apoptotic changes are evident by various measurements, including annexin V
binding, Hoechst 33342 staining, TUNEL labeling, DNA laddering, oligonucleosome
formation, caspase activation, up-regulation of pro-apoptotic proteins (Fas, FasL, Bax, p53),
and down-regulation of anti-apoptotic proteins such as Bcl-2 and FLIP-l. Since most cell types
are more susceptible to apoptosis in vitro than in vivo, demonstration of epidermal cell apoptotic
response to pemphigus autoantibodies in an in vivo model is required to establish the pathogenic
relevance of these mechanisms. In this study, using the passive transfer mouse model of PF,
we provide the first evidence that a pro-apoptotic response in the epidermal cells occurs during
the development of experimental PF. Moreover, we show that administration of caspase
inhibitors abolishes PF IgG-induced intraepidermal blisters and clinical disease in mice.
MATERIAL AND METHODS
Pemphigus IgG preparation
Sera from two patients with classic clinical and histological features of PF were used for IgG
preparation. The two sera contain IgG autoantibodies against the epidermal intercellular
substance, showing the indirect immunofluorescense titer of 1:320 for PF1 and 1:640 for PF2.
Both sera contained IgG autoantibodies to Dsg1 as determined by immunoprecipitation and
ELISA. A normal donor serum with a negative anti-epidermal autoantibody titer was included
as a control. The IgG fraction was prepared from the sera by ammonium sulfate precipitation
followed by extensive dialysis.
Li et al. Page 2














Breeding pairs of BALB/c mice were obtained from the Jackson Laboratory (Bar Harbor, ME)
and maintained at the Division of Laboratory of Animal Medicine Facility, University of North
Carolina at Chapel Hill (UNC-CH). Neonatal BALB/c mice (1 to 2 days old with body weight
between 1.4 to 1.6 g) were used for IgG passive transfer experiments. Animal care and animal
experiments were approved by the Institutional Animal Care and Use Committee at UNC-CH
and were in accordance with NIH guidelines.
Induction of experimental PF
Mouse models of PF were induced by IgG passive transfer experiments using a modified
protocol originally described (5,6). The IgG isolated from PF1 and PF2 sera were used
individually for disease induction. Briefly, various doses of PF IgG in a total volume of 50 µl
were administrated to neonatal mice by a single subcutaneous (s.c) injection in the dorsal area.
Twenty hours after IgG injection, the extent of skin disease in the dorsal area of the animals
was evaluated and scored on a scale of 0 to 3+ as described previously (37). IgG from PF1 and
PF2 sera induced the same types of blisters clinically and histologically. The minimal dose of
PF1 or PF2 IgG that produced skin lesions equal or larger than 2+ was used for the rest of the
experiments. For time course studies, animals (two animals per time point) were sacrificed at
various time points (up to 24 h) post IgG injection. Skin samples from the dorsal area of each
animal were harvested for H&E staining, TUNEL assay, and Western blotting.
Inhibitor administration
Peptide-based caspase inhibitors Ac-Asp-Glue-Val-Asp-Ch2Cl (Ac-DEVD-cmk) and Boc-
Asp(OMe)-CH2F (Boc-D-fmk), purchased from Calbiochem (San Diego, CA), were dissolved
in dimethylsulfoxide and diluted in TBS-Ca++ buffer before use. The inhibitor (0.034–6.8 µg/
g body weight) or vehicle in 50 µl total volume was administrated to mice by two subcutaneous
injections. The first was given 1.5 h before the IgG injection and the second was delivered
concomitantly with IgG injection. The same dose of pathogenic PF IgG was used for
comparison of the effects of the inhibitor and the vehicle treatment.
Terminal deoxynucleotidyl transferase–mediated dUTP nick end-labeling (TUNEL) assay
The experimental mouse skin samples were fixed in 10% buffered formalin and embedded in
paraffin. Paraffin sections were subjected to TUNEL assay using the PopDETEK Green kit
(Enzo Life Sciences, Farmingdale, NY) according to the manufacture’s instructions. Briefly,
following deparaffinization and rehydration, sections were treated with proteinase K and
incubated with reaction mixture containing terminal deoxynucleotidyl transferase and
fluorescence-conjugated dUTP for 1 h at 37 °C. The labeled DNA was examined under a
fluorescence microscope.
ELISA-based nuclearsome assay
Epidermal sheets were obtained from mouse skin pieces and used for the nucleosome detection
assay using an ELISA kit from Roche Molecular Biochemicals (Mannheim, Germany)
according to the manufacture’s protocol.
Western blotting
Mouse skin proteins were extracted by homogenization. RIPA buffer (50 mM Tris-HCl, pH
7.4, 150 mM NaCl, 1% NP-40, 0.25% Na-deoxycholate, and 0.1% SDS ) containing 2 mM
PMSF and proteinase inhibitor cocktail (Sigma) was used for Bax, Bcl-xl, and caspase
expression. SDS buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS, and 10% Glycerol) was used
for detection of cleaved acinus. Proteins were separated by SDS-PAGE and transferred to
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PVDF membranes. Blots were blocked with 5% nonfat dry milk in Tris-buffered saline
containing 0.1% Tween-20 for 1 hour. Blots were then incubated with primary antibodies
overnight at 4 °C followed by incubation with appropriate secondary antibodies conjugated
with horseradish peroxidase. Chemiluminescene was performed with Supersignal reagents
(Pierce Biotechnology, Rockford, IL). The primary antibodies used include antibodies to Bax,
Bcl-xl, cleaved caspase-3 and caspase-6 (Cell Signaling Technology), and to cleaved acinus
(Santa Cruz).
Statistics
The data were expressed as mean ± SD and were analyzed using the Student’s t test. A p< 0.05
was considered statistically significant.
RESULTS
PF IgG administrated in vivo induced DNA fragmentation in the epidermal cells
To evaluate whether PF autoantibodies are able to induce an apoptotic response in vivo, we
first conducted the IgG passive transfer experiments and then examined the epidermal cell
DNA fragmentation by TUNEL staining. Twenty hours after IgG injection, TUNEL-positive
epidermal cells were detected along the roof and the floor of the intraepidermal vesicle in the
skin sections from mice (n=6) injected with PF IgG isolated from PF1 or PF2 sera, but not
from control mice injected with normal human IgG (n=3). Representative results are shown in
Figure 1A To verify the induction of DNA fragmentation by PF IgG, we further examined the
presence of oligonucleosomes in the cytoplasmic fractions of lysates from epidermis of mice
injected with IgG using an ELISA-based assay. We found that PF IgG significantly increased
the oligonucleosomes in these fractions, compared with the lysates of epidermis of mice
injected with normal human IgG (Figure 1B).
We then performed time course studies to determine the temporal relationship between the
appearance of TUNEL-positive cells and the onset of histological blisters induced by PF IgG.
PF1 IgG was injected into mice subcutaneously. At various time points post IgG injection,
mice (n=2, each time point) were terminated. Skin specimens from the injected area of each
animal were taken for TUNEL and histological examination. Figure 2 shows the representative
results of TUNEL and H&E staining on the same set of mouse skin specimens obtained at
various time points following IgG injections. TUNEL-positive epidermal cells were first
detected at 8 h post PF IgG injection, whereas initial histological blisters appeared at 12 h. The
number of TUNEL-positive cells increased at 12 h and remained steadily at 24 h, when clinical
disease was fully developed. Consistent results were observed on the other set of samples from
the duplicated mice. In addition, the experiment (n=2, each time point) was repeated using the
second patient IgG. Similarly, IgG from PF2 also induced positive TUNEL epidermal cells
from 8 h afterward and limited histological blisters at 12 h and extensive blisters at 24 h (data
not shown). These results demonstrate that the appearance of TUNEL-positive epidermal cells
precedes the onset of histological blisters.
Up-and down-regulation of apoptotic regulators
We next performed Western blot analysis to examine the expression of the pro-apoptotic factor
Bax and the anti-apoptotic factor Bcl-xl in the skin extracts of mice injected with PF1 IgG. We
found that administration of PF1 IgG slightly up-regulated the expression of Bax at 2 and 4 h
and remarkably down-regulated the expression of Bcl-xl at 6, 8 and 20 h (Figure 3A). These
findings further support that a pro-apoptotic response is provoked in the skin cells of mice
injected with PF1 IgG.
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Expression of the active form of caspase-3 and –6 and cleavage of caspase-3 substrate
acinus
We further evaluated the activation of caspase-3 and -6 during the development of epidermal
blisters in neonatal mice injected with PF1 IgG. As shown in the top panel of Figure 3B, a
monoclonal antibody specific for the cleaved caspase-3 detected the processed active form of
caspase-3 (p17) in the mouse skin extracts at time points 6, 8 and 20 h post PF IgG injection.
At 20 h, two bands (p17 and p19) with reduced intensity were detected, indicating that
caspase-3 was not processed efficiently at this late time point. When the blot was reprobed
with a polyclonal antibody that recognizes both the unprocessed (inactive) and processed
(active) caspase-6, the unprocessed caspase-6 (35 kDa) was detected throughout the time
points, but the intensity level was dramatically reduced at 6 and 8 h and moderately reduced
at 20 h (Figure 3B, the second panel from the top). The fully processed caspase-6 (p15) was
detected at 6 and 8 h (Figure 3B, the third panel from the top). Additional bands (p18 and p20)
were observed at 6 and 8, and 20 h, which are likely the products of partially processed
caspase-6. In addition, we also detected the cleaved acinus (23 kDa), a caspase-3 substrate, at
8 h post PF1 IgG injection (Figure 3C).
Administration of caspase inhibitors protects mice from developing PF
To test the role of caspase-3 in PF IgG pathogenicity, we further evaluated whether caspase
inhibitors would have beneficial effect on PF model mice. We first assessed the effect of various
doses of Ac-DEVD-cmk, a cell-permeable and irreversible inhibitor for caspase-3/7, on PF1
IgG-induced disease. Control mice that received the vehicle developed skin lesions 20 h post
PF1 IgG injection (Figure 4A, and 4B panel a). In sharp contrast, mice that received the inhibitor
were protected from disease in a dose-dependent manner, in a range of 0.034 to 3.4 µg per
gram body weight (Figure 4A). When the dose was equal or larger than 3.4 µg/g body weight,
Ac-DEVD-cmk blocked disease completely (Figure 4A, also see Table I). Figure 4B is the
representative results derived from mice treated with the vehicle alone (left panel) or Ac-
DEVD-cmk (6.8 ug/g body weight) (right panel). Twenty hours post PF1 IgG injection, mice
treated with the vehicle revealed skin lesions and intraepidermal cleft at the upper layer (Figure
4B, panels a and b), mimicking the human disease. In contrast, the same dose of PF1 IgG failed
to induce clinical or histological blisters in mice that received Ac-DEVD-cmk (Figure 4B,
panels d and e). TUNEL assay revealed a positive staining on the epidermis from mice treated
with the vehicle (Figure 2B, panel c), but a negative staining from mice treated with Ac-
DEVDcmk (Figure 4B, panel f).
The effect of Ac-DEVD-cmk on skin blistering was also tested on mice induced by IgG from
PF2 serum. The same beneficial effect was observed (Table I). In addition to Ac-DEVD-cmk,
we also tested the effect of Boc-D-fmk, a broad-spectrum caspase inhibitor on experimental
PF. Boc-D-fmk (6.8 ug/g body weight) exhibited a similar protective effect against PF IgG-
induced histological blister and clinical disease (Table I).
DISCUSSION
The aim of this study was to investigate the relevance of the apoptotic mechanism in cell/tissue
injury in PF, an organ-specific autoantibody-mediated autoimmune blistering disease. Our
study provides five lines of evidence that pathogenic PF IgG is able to provoke the biochemical
response of apoptosis in epidermis of the mouse model. As a consequence, caspases are
activated, which contribute to the development of acantholytic blisters and disease
pathogenesis.
First, we demonstrated that administration of PF IgG to neonatal mice triggered DNA
fragmentation of lesional epidermal cells as demonstrated by two techniques, the TUNEL assay
Li et al. Page 5













and the nucleosome release assay. The former labels the free 3’-OH ends of the DNA strands
resulting from DNA breaks, and the latter measures the amount of oligonucleosomes released
in the cytosolic fraction of the epidermal cells. TUNEL-positive epidermal cells were detected
on the roof and floor of the intraepidermal blisters of the PF mice (Figure 1A). Consistent with
the TUNEL result, the nucleosome release assay also reveals increased epidermal DNA
fragmentation in lysates of the lesional skin of animals injected with PF IgG (Figure 1B). These
results are not only in line with previous findings in lesional epidermis of PF and PV patients
(33–35, 38), but also demonstrate a cause–effect relationship between the injected PF
autoantibodies and DNA fragmentation. Together, the data generated in the mouse model and
the previous observations in patients strongly suggest that apoptotic DNA fragmentation is
associated with the ongoing acantholysis induced by PF IgG.
Second, we observed that the appearance of TUNEL-positive epidermal cells precedes the
onset of intraepidermal blisters in neonatal mice injected with PF IgG (Figures 2). The time
course study of the model mice post PF IgG injections revealed that the TUNEL-positive
epidermal cells first appeared at 8 h, whereas the initial histological blisters occurred at 12 h.
This observation argues against the possibility that the apoptotic response to PF autoantibodies
is the result of the intraepidermal blistering. It has been previously reported that TUNEL-
positive epidermal cells are present not only in lesional epidermis but also in perilesional or
apparently normal epidermis of patients with PF and PV, suggesting that apoptosis may precede
the onset of acantholysis (33–35, 38). The current time course study provides direct evidence
that the occurrence of apoptotic DNA fragmentation of epidermal cells precedes intraepidermal
blister formation and clinical disease.
Third, we detected up- and down- expression of Bax and Bcl-xl, two Bcl-2 family members
exhibiting opposite effects in regulating apoptotic cell death via the mitochondrial pathway
(39). Western blot analysis of skin lysates of PF IgG-injected animals revealed an increased
amount of the pro-apoptotic factor Bax at earlier time points (2 and 4 h) and a decreased level
of the anti-apoptotic factor Bcl-xl at later time periods (6, 8 and 20 h) (Figure 3A). These results
indicate that the mitochondrial pathway of apoptosis might be evoked in the epidermal cells
by PF IgG.
Fourth, we detected the activated form of two effector caspases, caspase-3 and caspase-6, by
Western blotting of skin lysates from mice injected with PF IgG. Both caspase-3 and -6 were
activated at later time points (6, 8, and 20 h) post PF IgG injection (Figure 3B). The experiment
was repeated using a second IgG from PF2, and similar time-dependent expression of the
cleaved caspase 3 was also observed (data not shown). Further, cleaved caspase 3 was not
detected in the skin lysate of the mice that were injected with normal human IgG (data not
shown). To further verify the activation of caspase-3, we examined the cleavage of the protein
acinus, which is a substrate for caspase-3 and functions in inducing chromatin condensation
(40). We found that the activated form of acinus (23-kDa) was transiently expressed in mouse
skin following the injection of PF IgG (Figure 3C). However, we did not detect the 85-kDa
cleaved fragment of poly-(ADP-ribose) polymerase (PARP), another well-known substrate for
caspase-3 (data not shown). Failure to detect the cleaved PARP fragment may indicate that the
level of caspase-3 activity in the epidermis of mice injected with PF IgG is low or limited.
Caspase-3 activity has been detected in cultured keratinocytes exposed to PV IgG (31, 35,
41). Interestingly, Frusic-Zlotkin et al. (41) found that the induced caspase-3 activity level
roughly correlated with the IF titers of the PV sera utilized. The result of the present study
demonstrates for the first time that caspase-3, as well as caspase-6, is activated in vivo before
the onset of intraepidermal blistering.
Finally, another novel observation reported in this study demonstrates that two caspase
inhibitors were able to block the PF blistering in mice. Administration of the caspase-3/7
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selective inhibitor Ac-DEVD-cmk abrogated DNA fragmentation and protected mice from
developing intraepidermal blisters and clinical phenotype (Figure 4B). The inhibitor was
effective in a dose-dependent manner (Figure 4A). Moreover, the pan-caspase inhibitor Boc-
D-fmk was also effective in preventing skin disease in neonatal mice induced by PF IgG (Table
1). The protective effect of these inhibitors against PF IgG-induced skin blistering is more
likely a local effect since the inhibitors were delivered into the animals by local (s.c.) injections
and the skin blistering was examined only in the dorsal area where IgG was injected. Although
it is also possible that a small fraction of the injected inhibitors may diffuse into the
intravascular compartment, enter into the general circulation, and thus have some systemic
effect.
It has been reported that many peptide-based caspase inhibitors, such as z-VAD-fmk, z-DEVD-
fmk, and z-YVAD-fmk, also inhibit papain-like cathepsins at a higher concentration (100 µM)
commonly used for cell-based studies (42,43). However, the non-specific effects are only
observed in the fluromethylketone (-fmk) modified inhibitors, but not in the chloromethylketon
(-cmk) or aldehyde (-cho) modified inhibitors (42,43). Indeed, z-DEVD-cmk and z-DEVD-
cho do not exhibit any inhibitory effect on cathepsin activity at the high concentration of 100
µM when tested in cells (43). The finding in this study that local injection of Ac-DEVD-cmk
blocked experimental PF at the low-micro molar concentration range (5 µg/50 µl, < 0.2 µM)
indicates that the possible non-specific effect of this inhibitor on papain-like cathepsins is
negligible, if exists. Taken together, the protective effect of the caspase inhibitors on PF
strongly suggest that caspase activation is critically involved in the formation of acantholytic
blisters and subsequent clinical disease of PF.
Collectively, the results of this study suggest that PF IgG induces a pro-apoptotic response in
epidermal cells of the neonatal mice. As a consequence, executioner caspases are activated and
contributes to intraepidermal blistering. The observation that the cleaved caspase-3 and -6 are
detected at late time points (6 h and afterward) indicates that activation of these executioner
caspases is a downstream event proximal to the onset of histological blistering of PF. Possible
upstream apoptotic pathways may include the mitochondrial pathway as well as the death
receptor pathway. The former possibility is supported by the observation that Bax is
upregulated at 2 h post PF IgG injection. Activation of the death receptor pathway is also
possible as increased expression of Fas, Fas ligand and activated initiator caspase-8 in this
pathway have been detected in lesional skin biopsy of PV patients and in cultured keratinocytes
exposed to PV IgG (34,35,41). In addition, it has been found that two signaling events, the p38
MAPK activation and the RhoA inactivation, are involved in acantholysis induced by PF IgG
as well as PV IgG (26,28). The pathogenic role of these two signaling pathways in PF and PV
are demonstrated by blocking skin blistering using pharmacologic inhibitors of p38 MAPK
(22) or activator of RhoA (26). While the relationship of the RhoA inactivation to the apoptotic
pathway is not clear, p38 MAPK activation is known to be an upstream event of keratinocyte
apoptosis (44). Indeed, s.c. injection of a p38 MAPK inhibitor prevents PF IgG-induced
keratinocyte apoptosis in mice (David Rubenstein, personal communication), indicating that
apoptosis is one of the downstream events following p38 MAPK activation in PF mouse model.
An intriguing observation in this study is that although we detected the key biochemical
hallmarks of apoptosis (caspase-3 activation and DNA fragmentation), the morphological
characteristics of apoptosis are not obvious by H&E examination of the epidermis of mice
injected with pathogenic PF IgG. This observation may suggest that activation of caspases
leads to epidermal cell injury and dysfunction, which in turn is manifested as epidermal cell
detachment and blister formation. Acantholytic blisters may occur before or without the
endpoint of epidermal cell death. Caspase-3 activation without cell death has been reported in
several physiological processes such as terminal differentiation of various cell types,
proliferation of resting peripheral T lymphocytes, and inhibition of the cell cycle in peripheral
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B cells (45). It is unclear how cells are able to survive with an activated “killer” caspase. It has
been suggested that compartmentalized or low magnitude activation of caspase-3, or activation
of pro-survival factors may account for this enigma. Regardless of the possible explanation,
we hypothesize that the contribution of activated executioner caspases to the process of
epidermal cell detachment is through proteolytic cleavage of structural proteins involved in
epidermal cell-cell adhesion. It should be noted that acantholysis is a process of the loss of
cell-cell cohesion, and the formation of intraepidermal cleft is a result of this process.
Therefore, although our time course study clearly shows that the activation of caspase-3 and
-6 is prior and close to the onset of visible intraepidermal cleavage, it does not exclude the
possibility that the acantholytic process has not started before executioner caspases are
activated. It is probable that weakened intercellular adhesion and some extent of acantholysis
already occurred at early course. Activation of executioner caspases may be one of the later
events that aggravate this process by proteolytic cleavage of structural proteins involving the
epidermal cell-cell junctions. Possible candidates may include components of the desmosomes,
adherens junctions, and cytoskeletons. Many cell adhesion molecules are caspase substrates
(46) or are degraded during apoptosis, such as Dsg1 (47,48), Dsg3, plakoglobin, plakophillin,
plakin proteins (49–51), E-cadherin, P-cadherin and β-catenin (46). Interestingly, it has been
shown that shedding of the ectodomain of Dsg1 or Dsg3 during the process of apoptosis is
inhibited by caspase inhibitors (47,51).
Apoptotic epidermal keratinocytes have been found in cutaneous diseases such as lichen
planus, atopic dermatitis, and toxic epidermal necrolysis. Excessive apoptosis of keratinocytes
at basal or suprabasal layers of the epidermis is thought to account for the characteristic
histological features found in lichennoid tissue reaction, which is characterized by the presence
of colloid bodies and basal cell damage (52), and in atopic dermatitis characterized by
suprabasal intercellular edema (spongiosis) and vesicle formation (53). Massive apoptotic cell
death is recognized as a key mechanism involved in the pathogenesis of toxic epidermal
necrolysis (54,55), in which the epidermis is detached from the dermis due to the loss of
adhesion between the basal cell and its underlying extracellular matrix. Apparently, the
apoptotic mechanism is only part of the complex pathogenic mechanisms underlying these
diseases, and apoptosis alone may not explain the distinct histological presentations of these
diseases. Other factors may also account for the different forms of epidermal injury caused by
keratinocyte apoptosis. These may include the trigger of apoptosis, the magnitude of apoptotic
response, the other pathways that are activated concurrently, and the unique feature of the target
layer of the epidermis (basal, spinous, or granular keratinocytes).
In summary, the finding of this mouse model study suggests that the biochemical pathway of
apoptosis is involved in the epidermal cell/tissue injury of PF, an organ-specific autoimmune
disease. Activated caspases may be one of the final events that contribute to acantholytic
blistering. Further studies are required to identify the potential targets for caspases that may
be cleaved during PF blistering.
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Figure 1. Induction of DNA fragmentation in the mouse epidermal cells following PF IgG passive
transfer
(A) TUNEL staining. Neonatal mice were injected (s.c.) with pathogenic PF or normal human
IgG. Skin samples were obtained 20 h post IgG injections and subjected to TUNEL staining.
Positive TUNEL labeling was revealed in the epidermis from mice (n=6) injected with IgG
from PF1 or PF2, but not from control mice (n=3) injected with the normal human IgG.
Representative results are shown. v: vesicle. (B) Oligonucleosome releasing assay. DNA
oligonucleosomes presented in the cytoplasmic fractions of mouse epidermal sheets obtained
from control mice (n=2) and PF mice (n=2) were analyzed with an ELISA-based assay for
presence of the histone-DNA complex.
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Figure 2. Temporal relationship between TUNEL-positive cells and histological blisters
Neonatal mice (n=2, each time point) were injected (s.c.) with pathogenic PF1 IgG and
terminated at various time points post IgG injection. Skin specimens were obtained and
subjected to TUNEL labeling and H&E staining. As shown in these representative results,
TUNEL-positive cells were first detected at 8 h, whereas initial histological cleft was revealed
at 12 h post IgG injection. Similar temporal relationship between TUNEL-positive cells and
histological blisters was also observed using IgG isolated from PF2 serum.
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Figure 3. Expression of apoptotic mediators during the development of experimental PF
At various time points post PF1 IgG injection, mouse skin specimens were harvested, pooled
(n=2, each time point), and extracted. The extracts were subjected to Western blot analysis
using a polyclonal antibody for Bax, a monoclonal antibody to Bcl-xl (A), a monoclonal
antibody specific for the cleaved caspase-3, a polyclonal antibody for cspase-6 (cleaved and
procaspase-6) (B), or a polyclonal antibody against the cleaved acinus (23 kDa) (C). β-actin
was detected for protein loading controls. As shown, the level of pro-apoptotic factor Bax was
slightly increased at 2 and 4 h, whereas the anti-apoptotic factor Bcl-xl expression was reduced
markedly at 6, 8, and 20 h. The cleaved (activated) of caspase-3 and -6 were detected by 6, 8,
and 20 h after IgG injection. Acinus cleavage was revealed transiently at 8 h.
Li et al. Page 14













Figure 4. The caspase-3/7 inhibitor Ac-DEVD-cmk protects mice against PF
(A) Dose-dependent protective effects. Various doses of caspase-3/7 inhibitor Ac-DEVD-cmk
were administrated into neonatal mice by two subcutaneous injections. Half of the dose was
given 1.5 h before IgG injection, and the second half dose was injected concomitantly with
PF1 IgG. Control mice were injected with vehicle. The same dose of pathogenic PF1 IgG was
used for disease induction in each experiment. The extent of disease was examined and scored
20 h post IgG injection. The protective effect is highly significant (n=8 for the control group,
n=3 for each treatment group, *p<0.001, Student t-test). (B) Suppression of TUNEL-staining
and blockade of intraepidermal blisters and clinical disease. Neonatal mice were injected with
pathogenic PF1 IgG with (d–f) or without (a–c) Ac-DEVD-cmk. Control mice treated with
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vehicle developed clinical and histological blisters (a and c) 20 hours post IgG injection. In
contrast, mice treated with the caspase-3 inhibitor did not develop clinical and histological
lesions (d and f). TUNEL assay showed a positive staining in control mice but not in mice
treated with the inhibitor (e).
Li et al. Page 16

























Li et al. Page 17
Table I
Blockade of experimental PF by the caspase inhibitors*
IgG injected Treatment # of mice Disease Score
(Mean ± SD)
PF1 Vehicle 8 2.5 ± 0.3
Ac-DEVD-cmk 6 0
Boc-D-fmk 3 0




Neonatal mice were preinjected (s.c.) with the caspase inhibitor or control vehicle. One and a half hour later, mice were injected (s.c.) with the pathogenic
IgG prepared from two PF patients (PF1 and PF2) along with the inhibitor or vehicl. The total doses for Ac-DEVD-cmk were 3.4 or 6.8 µg/g b.w. and
for Boc-D-fmk was 6.8 µg/g b.w. Injected animals were examined clinically 20 h after IgG injection, and clinical disease was scored. There is a significant
difference in clinical disease scores between mice treated with vehicle and mice treated with Ac-DEVD-cmk or Boc-D-fmk (p < 0.0001, Student’s t test).
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